ArticleJournal of cardiothoracic surgery2025
Extracorporeal membrane oxygenation in a low-volume whole nation cardiothoracic centre: short- and long-term mortality, survivors` quality of life and symptoms of post-traumatic stress disorder.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor over three decades ECMO-treatment has been provided in our low-volume nationwide cardiothoracic centre in Iceland. This research aims to examine both the short- and long-term results of all adult ECMO-cases at our centre, including health-related quality of life (HrQoL), return to work status and symptoms of post-traumatic stress disorder (PTSD).
methodsA retrospective study including all adult patients treated with ECMO in a single university cardiothoracic centre in Iceland between 2002 and 2022. Five-year survival was evaluated with Kaplan-Meier estimates, HrQoL with the EQ-5D-5 L instrument and PTSD with the LEC and PLC-5 check lists assessing traumatic life events and PTSD symptoms, respectively. Median follow-up time was 6.5 yrs.
resultsNinety-three patients received ECMO during the study period, an average of 5.2 patients per year since 2006. Sixty-six patients received venoarterial (VA) ECMO, of whom 28 (42%) could be weaned and 21 (32%) survived to discharge. Twenty-seven patients received venovenous (VV) ECMO, with 18 (67%) surviving to discharge. Twenty-four out of 30 living patients completed follow-up questionnaires. No problems with an EQ-5D-5L domain was reported 21 times in the VA ECMO group and 33 times in the VV ECMO group. Three out of four patients reported problems with anxiety or depression. Six patients (25%) met screening criteria for PTSD. At the end of follow-up, 2/12 VA ECMO and 8/12 VV ECMO patients had returned to work .
conclusionsECMO treatment can be provided with acceptable short- and long-term mortality in a low-volume centre. Nonetheless, opportunities for improvement could be identified, particularly regarding VA ECMO in cardiac arrest. At long-term follow-up, problems with anxiety and/or depression were most commonly observed and 25% met screening criteria for PTSD. Most VA ECMO surviors did not return to work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.